Covid testing pioneer named as a BioBusiness Mover and Shaker

Dr Sally Price, Head of Cell and Translational Science at Medicines Discovery Catapult (MDC) has been named in BioBeat’20 Movers & Shakers in BioBusiness 2020.

Selvita to acquire Fidelta from Galapagos

Strengthening Selvita’s position as one of the largest preclinical contract research organizations in Europe - Acquisition substantially expands Selvita’s integrated drug discovery services offering - Transaction will almost double Selvita’s revenues - Enterprise value of € 31.2M to be paid in cash - Fidelta to continue performing drug discovery services for Galapagos for the next five years

CEO Update | Monday 23 November

The news that we’ve all been waiting for is out today, from the UK-sourced Oxford University and AstraZeneca COVID-19 vaccine. The great news is that the vaccine works in Phase III clinical trials. For an industry audience it is worth digging into the complex dataset.

BIA launches report on rare disease medicines appraisal

The BioIndustry Association's Rare Disease Industry Group (RDIG) has today launched A Rare Chance for Reform in collaboration with PwC, calling for action to ensure that patients are able to access innovative medicines for rare diseases.

Pharmaceutical Investment Recovery & Redeployment Solutions

Sell or redeploy equipment from multiple sites within your company with EquipNet’s Surplus Asset Management Program.

Abzena upgrades GMP chemistry and conjugation suites to allow Phase III and commercial manufacturing

Abzena, a global partner research organization for integrated bench to market solutions for biologics and bioconjugates, has announced upgrades of its chemistry GMP suites.

Squeezed government biomedical innovation budget puts future medicines at risk, FOI reveals  

Insufficient government funding is putting the UK’s pipeline of future biomedical innovations at risk, according to data revealed in a Freedom of Information (FOI) request.  

CEO Update | Monday 16 November

Breaking news today that Moderna has released initial data on their mRNA vaccine’s Phase 3 study, which met statistical criteria with a vaccine efficacy of 94.5%. The phase 3 trial was conducted in the US in partnership with BARDA and Operation Warp Speed and based on these interim safety and efficacy data, Moderna intends to submit an application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) in the coming weeks. It’s great news and following last week’s announcement by Pfizer/Biontech, shows the importance of smaller biotech companies in our innovation ecosystem.

Government confirms R&D tax credit cap exemption to protect genuine biotech companies

Draft legislation to implement the SME R&D tax credit PAYE cap published yesterday (12 November) confirms that the Government intends to implement a targeted exemption to protect genuine companies, as proposed by the BIA.

Life science VC investments perform equally or better than other sectors, new data shows

A report published today by the British Business Bank is the most comprehensive analysis of UK life science venture capital performance to date, and it reveals that life science investments have performed equally or better than those in non-life sciences.